Rajkumar Verma

About

Dr. Verma's unwavering dedication lies at the crossroads of pharmacology and neuroscience research, where his passion for pioneering drug discovery shines brilliantly in the context of ischemic stroke treatment. With a journey marked by persistent curiosity, he embarked on a transformative path. Having completed his Ph.D. at Central Drug Research Institute in Lucknow, India, Dr. Verma's academic journey took a significant step forward with the attainment of his doctoral degree in Pharmacy from Birla Institute of Technology, Mesra, Ranchi, India. These academic pursuits laid the groundwork for his impactful career. In February 2012, Dr. Verma found a new home at UConn Health to continue his interest in stroke therapy.

Employment

• University of Connecticut School of Medicine Assistant Professor
  2012 - Present

Education

• Central Drug Research Institute PhD
  2006 - 2011

Projects & Funding

Projects & funding information is unavailable.

Publications (44)

• Novel P2X4 Receptor Antagonist MRS4719 Improves Ischemia/reperfusion Injury in Mice
  Medicinal Chemistry Research 2026 DOI: 10.1007/s00044-026-03568-9
  +Save
• Robean: A Standalone Freeware for Automated Rodent Neurobehavioural Analysis with Integrated Tracking, Visualization, and Reporting
  2026 DOI: 10.64898/2026.07.11.737999
  +Save
• Generation of miR-141/200c conditional knockout mice from knockout-first, reporter-tagged parent and functional validation of the floxed allele
  2025 DOI: 10.1101/2025.09.02.673774
  +Save
• Exploring the therapeutic potential of sγPNA-141: Pharmacodynamics and mechanistic insights during ischemic stroke recovery
  Molecular Therapy Nucleic Acids 2024 DOI: 10.1016/j.omtn.2024.102355
  +Save
• Revealing the Novel Role of Purinergic Receptor P2X4 in Phagocytic Uptake After Ischemic Stroke
  Journal of the American Heart Association 2024 DOI: 10.1161/JAHA.124.037148
  +Save
• AI is a viable alternative to high throughput screening: a 318-target study.
  Scientific reports 2024 DOI: 10.1038/s41598-024-54655-z
  +Save
• The Implant-Induced Foreign Body Response Is Limited by CD13-Dependent Regulation of Ubiquitination of Fusogenic Proteins
  The Journal of Immunology 2024 DOI: 10.4049/jimmunol.2300688
  +Save
• Transcriptomic analysis reveals novel age-independent immunomodulatory proteins as a mode of cerebroprotection in P2X4 receptor knockout mice after ischemic stroke
  Purinergic Signalling 2023 DOI: 10.1007/s11302-023-09956-9
  +Save
• Fluorescent liposomal nanocarriers for targeted drug delivery in ischemic stroke therapy
  Biomaterials Science 2023 DOI: 10.1039/D3BM00951C
  +Save
• Transcriptomic analysis reveals novel age-independent immunomodulatory proteins as a mode of cerebroprotection in P2X4R KO mice after ischemic stroke
  Research Square 2023 DOI: 10.21203/rs.3.rs-2747807/v1
  +Save